S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-3.32%) $1.920
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Actualizaciones en tiempo real para Crinetics Pharmaceuticals [CRNX]

Bolsa: NASDAQ Sector: Healthcare Industria: Biotechnology
Upcoming Earnings Alert

5 days till quarter result
(bmo 2024-05-02)

Expected move: +/- 6.95%

BUY
80.00%
return -2.31%
SELL
40.00%
return 0.89%
Última actualización26 abr 2024 @ 16:00

-0.40% $ 42.12

COMPRAR 104428 min ago

@ $36.22

Emitido: 14 feb 2024 @ 15:47


Retorno: 16.29%


Señal anterior: feb 14 - 12:28


Señal anterior: Vender


Retorno: -0.41 %

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):
Profile picture for Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors...

Stats
Volumen de hoy 551 185
Volumen promedio 798 153
Capitalización de mercado 3.28B
EPS $0 ( 2024-02-28 )
Próxima fecha de ganancias ( $-0.840 ) 2024-05-02
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -11.41
ATR14 $0.0550 (0.13%)
Insider Trading
Date Person Action Amount type
2024-04-18 Struthers Richard Scott Sell 350 Common Stock
2024-04-15 Pizzuti Dana Sell 14 375 Stock option (Right to Buy)
2024-04-15 Pizzuti Dana Buy 14 375 Common Stock
2024-04-15 Pizzuti Dana Sell 14 375 Common Stock
2024-04-15 Struthers Richard Scott Buy 20 000 Common Stock
INSIDER POWER
20.03
Last 99 transactions
Buy: 1 532 159 | Sell: 1 109 365

Volumen Correlación

Largo: -0.22 (neutral)
Corto: 0.79 (moderate)
Signal:(66.221) Neutral

Crinetics Pharmaceuticals Correlación

10 Correlaciones Más Positivas
VYNE0.883
CPIX0.875
FULC0.871
ARWR0.869
RDUS0.866
LITM0.861
RNDM0.858
SPRO0.857
JAKK0.844
ENTA0.841
10 Correlaciones Más Negativas
ALGM-0.894
SITM-0.856
GMII-0.853
PPBT-0.85
GDRX-0.835
UMPQ-0.821
GFS-0.815
SBBP-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Crinetics Pharmaceuticals Correlación - Moneda/Commodity

The country flag 0.71
( moderate )
The country flag 0.56
( weak )
The country flag 0.00
( neutral )
The country flag 0.08
( neutral )
The country flag -0.04
( neutral )
The country flag -0.27
( neutral )

Crinetics Pharmaceuticals Finanzas

Annual 2023
Ingresos: $4.01M
Beneficio Bruto: $2.92M (72.64 %)
EPS: $-3.69
FY 2023
Ingresos: $4.01M
Beneficio Bruto: $2.92M (72.64 %)
EPS: $-3.69
FY 2022
Ingresos: $4.74M
Beneficio Bruto: $3.35M (70.68 %)
EPS: $-3.08
FY 2021
Ingresos: $1 078.00
Beneficio Bruto: $1 078.00 (100.00 %)
EPS: $-0.00280

Financial Reports:

No articles found.

Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico